Market Place
Sourcing Support
Metsera Closes IPO & Full Exercise of Underwriters’ Option
05 Feb 2025 //
GLOBENEWSWIRE
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut
01 Feb 2025 //
REUTERS
Metsera targets up to $1.78 billion valuation in US IPO
28 Jan 2025 //
REUTERS
Obesity biotech Metsera files for a swift IPO
11 Jan 2025 //
FIERCE BIOTECH
Weight-loss drug developer Metsera reveals wider loss in IPO
10 Jan 2025 //
REUTERS
Metsera Touts ‘Powerful’ Weight Loss Results
08 Jan 2025 //
BIOSPACE
Altasciences Supports Metsera in Obesity Clinical Trials
21 Nov 2024 //
BUSINESSWIRE
Metsera Raises Another $215M for Long-Acting GLP-1
14 Nov 2024 //
BIOSPACE
Metsera Raises $215M for Long-Acting GLP-1 Obesity Treatment
13 Nov 2024 //
BIOSPACE
Amneal And Metsera Partner On Next-Gen Obesity Medicines
01 Oct 2024 //
BUSINESSWIRE
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
24 Sep 2024 //
FIERCE BIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.